DMK Pharmaceuticals Corporation

0.50 USD
-0.10 (-16.25%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

DMK Pharmaceuticals Corporation stock is up 2.55% since 30 days ago. The next earnings date is Feb 18, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.83% of the previous 28 December’s closed higher than November. 100% of analysts rate it a buy.

About DMK Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis.